Ascendiant Capital Markets Raises Myomo (NYSEAMERICAN:MYO) Price Target to $11.00

Myomo (NYSEAMERICAN:MYO) had its price objective lifted by Ascendiant Capital Markets from $9.00 to $11.00 in a research report report published on Monday morning,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

Other equities analysts also recently issued reports about the company. Alliance Global Partners reiterated a “buy” rating on shares of Myomo in a research note on Tuesday, March 11th. HC Wainwright lifted their target price on Myomo from $7.50 to $9.50 and gave the company a “buy” rating in a research note on Wednesday, March 12th. Finally, Craig Hallum boosted their price objective on Myomo from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, March 11th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $9.75.

Myomo Stock Performance

NYSEAMERICAN:MYO opened at $5.48 on Monday. Myomo has a 12 month low of $2.51 and a 12 month high of $7.17. The stock has a market capitalization of $165.77 million, a price-to-earnings ratio of -23.83 and a beta of 1.68.

Insider Buying and Selling

In other news, Director Thomas F. Kirk bought 7,400 shares of the business’s stock in a transaction on Thursday, March 13th. The stock was purchased at an average price of $5.00 per share, with a total value of $37,000.00. Following the transaction, the director now directly owns 255,933 shares in the company, valued at approximately $1,279,665. The trade was a 2.98 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Harry Kovelman sold 30,000 shares of the business’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $5.50, for a total transaction of $165,000.00. Following the transaction, the insider now directly owns 97,973 shares of the company’s stock, valued at approximately $538,851.50. This represents a 23.44 % decrease in their position. The disclosure for this sale can be found here. 4.54% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in MYO. Barclays PLC acquired a new position in Myomo in the third quarter worth about $36,000. BNP Paribas Financial Markets acquired a new stake in Myomo during the 4th quarter worth $64,000. Jane Street Group LLC acquired a new stake in Myomo during the 3rd quarter worth $65,000. Walleye Capital LLC bought a new position in shares of Myomo during the fourth quarter worth $66,000. Finally, Squarepoint Ops LLC bought a new stake in Myomo in the 4th quarter valued at $74,000. Institutional investors and hedge funds own 44.99% of the company’s stock.

Myomo Company Profile

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.